What is the P/E ratio of Ahlcon Parenterals (India)?

The latest standalone P/E ratio of Ahlcon Parenterals (India) as of 01-Jan-1970 is 0.00.

What is the P/B ratio of Ahlcon Parenterals (India)?

The latest standalone P/B ratio of Ahlcon Parenterals (India) as of 01-Jan-1970 is 4.31.

What is the 52-week high and low of Ahlcon Parenterals (India)?

The 52-week high of Ahlcon Parenterals (India) is Rs. 517.25 and the 52-week low is Rs. 514.75.

Ahlcon Parenterals (India) Ltd - Stock Valuation and Financial Performance

Name: Ahlcon Parenterals (India)
Brand: Ahlcon Parenterals (India)

BSE: 524448 | NSE: | Pharmaceuticals & Drugs | Small Cap

Place order

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Ahlcon Parenteral (I

Based on:

Data

M-Cap below 100cr DeciZen not available

Ahlcon Parenterals (India) stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

370.8 Cr.

52-wk low:

514.8

52-wk high:

517.3

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Ahlcon Parenteral (I:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	TTM
ROCE % ⓘ	21.5%	21.8%	8.8%	-0.7%	1.1%	-8.1%	-10%	1.7%	-12%	-1%	-
Value Creation Index ⓘ	0.5	0.6	-0.4	-1.1	-0.9	-1.6	NA	NA	NA	NA	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	108	120	116	119	135	150	156	174	132	176	176
Sales YoY Gr.	-	11.4%	-3.3%	2.6%	13.8%	10.5%	4%	12.1%	-24.2%	32.8%	-
Adj EPS ⓘ	17.7	27.1	24.6	-19.2	-11.8	-62.6	-67.1	-20.8	-64.6	-28.1	-27.5
YoY Gr.	-	53.3%	-9.2%	-178.1%	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	75.1	102.1	124.8	99	79.8	19.5	-46.6	-68.2	-133.5	-161	119.5
Adj Net Profit ⓘ	12.7	19.5	17.7	-13.8	-8.5	-45	-48.3	-15	-46.5	-20.2	-20
Cash Flow from Ops. ⓘ	9.3	17.1	31.2	7.8	12.7	34.7	38.7	30.3	21.4	11.5	-
Debt/CF from Ops. ⓘ	1.9	2.5	6.6	32.1	21.5	8.3	7.6	9.9	14.6	29.6	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	5.6%	5.4%	4.1%	32.8%
Adj EPS ⓘ	-205.3%	NA	NA	NA
BVPSⓘ	-208.8%	-215.1%	NA	NA
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	TTM
Return on Equity % ⓘ	26.2	30.4	21.7	-17.2	-13.1	-126	496.3	36.2	64.1	19.1	132.5
Op. Profit Mgn % ⓘ	22.9	28.7	23.1	12.6	19.8	12.8	7.7	18.9	3.9	15.2	25.6
Net Profit Mgn % ⓘ	11.8	16.3	15.3	-11.6	-6.3	-30.1	-31.1	-8.6	-35.2	-11.5	-11.3
Debt to Equity ⓘ	0.3	0.6	2.3	3.5	4.8	20.6	-8.8	-6.1	-3.3	-2.9	-
Working Cap Days ⓘ	107	122	149	152	140	141	153	137	149	117	90
Cash Conv. Cycle ⓘ	55	67	86	103	101	90	83	76	82	66	19

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Ahlcon Parenterals (India) Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-27.5	-
TTM Sales (₹ Cr.)	176	-
BVPS (₹.) ⓘ	119.5	-
Reserves (₹ Cr.) ⓘ	79	-
P/BV ⓘ	4.31	-
PE ⓘ	0.00	-

From the Market
52 Week Low / High (₹)	514.75 / 517.25
All Time Low / High (₹)	2.00 / 598.00
Market Cap (₹ Cr.)	371
Equity (₹ Cr.)	7.2
Face Value (₹)	10
Industry PE ⓘ	47.9

Management X-Ray of Ahlcon Parenteral (I:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Ahlcon Parenteral (I

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Ahlcon Parenteral (I

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22
Sales	107.71	119.97	115.98	119	135.39	149.66	155.65	174.47	132.31	175.67
Operating Expenses ⓘ	83.40	85.62	90.25	110.71	116.27	130.54	143.79	142.37	127.89	148.96
Manufacturing Costs	29.63	31.44	37.11	21.51	23.83	39.38	43.68	43.78	41.59	47.78
Material Costs	29.11	27.13	22.43	40.94	46.07	50.21	48.53	54.69	47.30	62.39
Employee Cost	14.57	15.88	17.67	22.45	24.56	22.38	24.11	26.14	23.69	26.18
Other Costs ⓘ	10.09	11.16	13.04	25.81	21.81	18.57	27.48	17.76	15.30	12.62
Operating Profit ⓘ	24.30	34.35	25.74	8.29	19.12	19.11	11.86	32.10	4.42	26.70
Operating Profit Margin (%)	22.6%	28.6%	22.2%	7.0%	14.1%	12.8%	7.6%	18.4%	3.3%	15.2%
Other Income ⓘ	0.95	0.74	0.39	0.64	0.65	4.03	1.83	1.47	1.41	4.61
Interest ⓘ	2.95	1.58	0.63	16.57	17.29	27.57	28.59	27.54	26.16	25.63
Depreciation ⓘ	3.61	3.44	4.61	16.13	16.30	38.99	32.68	21.61	26.70	25.47
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	18.69	30.06	20.89	-23.77	-13.82	-43.42	-47.57	-15.59	-47.03	-19.79
Tax ⓘ	5.82	10.56	3.87	-5.24	0	0	0	0	0	0
Profit After Tax	12.87	19.50	17.02	-18.53	-13.82	-43.42	-47.57	-15.59	-47.03	-19.79
PAT Margin (%)	11.9%	16.3%	14.7%	-15.6%	-10.2%	-29.0%	-30.6%	-8.9%	-35.5%	-11.3%
Adjusted EPS (₹)	17.8	27.0	23.6	-25.7	-19.2	-60.3	-66.1	-21.7	-65.3	-27.5
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22
Equity and Liabilities
Shareholders Fund	54.99	73.54	89.82	71.29	57.47	14.05	-33.53	-49.11	-96.14	-115.93
Share Capital ⓘ	8.10	7.20	7.20	7.20	7.20	7.20	7.20	7.20	7.20	7.20
Reserves ⓘ	46.88	66.34	82.62	64.09	50.26	6.85	-40.73	-56.31	-103.34	-123.13
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	13.01	40.20	206.16	250.70	273.57	188.92	295.79	301.27	245.40	339.30
Long Term Debt	2.92	20.02	181.76	182.08	100	94.65	75	143	75	253
Short Term Debt	10.09	20.18	24.40	68.62	173.57	94.27	220.79	158.27	170.40	86.30
Trade Payables	8.70	10.01	7.60	6.37	4.14	14.12	14.33	14.50	11.17	8.89
Others Liabilities ⓘ	18.01	18.80	34.75	30.57	27.73	114.53	43.98	27.37	104.72	42.73
Total Liabilities ⓘ	94.71	142.56	338.34	358.92	362.91	331.62	320.58	294.04	265.15	275
Fixed Assets
Gross Block	83.22	89.83	323.45	351.09	353.14	381.76	390.59	398.48	403.17	409.67
Accumulated Depreciation	36.72	40	45.73	61.86	78.11	113.91	144.78	165.87	192.57	215.15
Net Fixed Assetsⓘ	46.50	49.83	277.72	289.23	275.04	267.85	245.81	232.60	210.60	194.52
CWIP ⓘ	7.73	26.30	3.21	10.83	27.45	4.08	2.75	1.26	6.22	0.62
Investmentsⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	10.09	7.74	13.61	21.52	17.07	17.53	26.95	25.54	19.36	25.90
Trade Receivables	25.69	33.53	31.30	26.12	33.21	25.26	28.42	24.14	14.92	24.27
Cash Equivalents	0.58	17.08	0.86	1.76	0.53	0.55	0.61	0.40	0.31	15.13
Others Assetsⓘ	4.12	8.06	11.64	9.45	9.60	16.35	16.04	10.10	13.74	14.56
Total Assets ⓘ	94.71	142.56	338.34	358.92	362.91	331.62	320.58	294.04	265.15	275

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22
Cash Flow From Operating Activity ⓘ	9.31	17.13	31.17	7.80	12.73	34.67	38.74	30.33	21.42	11.47
PBT ⓘ	18.69	30.06	20.89	-23.77	-13.82	-43.42	-47.57	-15.59	-47.03	-19.79
Adjustment ⓘ	7.82	4.34	6.22	33.83	33.80	80.80	74.50	50.57	56.01	50.84
Changes in Working Capital ⓘ	-9.59	-6.27	10.67	-1.82	-6.77	-2.46	12.44	-5.24	12.11	-19.24
Tax Paid ⓘ	-4.81	-9.60	-6.33	-0.44	-0.48	-0.25	-0.62	0.59	0.32	-0.34
Cash Flow From Investing Activity ⓘ	-4.73	-25.23	-210.76	-34.96	-18.64	-9.81	-9.32	-9.18	-7.78	-3.68
Capex	-5.04	-25.47	-210.52	-35.26	-18.73	-10	-9.48	-9.35	-7.91	-3.79
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0.32	0.24	-0.24	0.30	0.08	0.19	0.15	0.17	0.13	0.11
Cash Flow From Financing Activityⓘ	-5.66	24.76	163.09	28.28	4.64	-24.80	-29.35	-21.36	-13.85	7.07
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-4.10	15.68	158.87	0.31	0	0	-25	0	0	0
Interest Paid ⓘ	0	0	0	-16.25	-18.46	-27.35	-36.22	-26.84	-25.98	-18.83
Dividend Paid ⓘ	-0.02	-0.11	0	0	0	0	0	0	0	0
Others ⓘ	-1.55	9.19	4.22	44.22	23.10	2.55	31.87	5.48	12.13	25.90
Net Cash Flow ⓘ	-1.08	16.66	-16.50	1.12	-1.27	0.05	0.07	-0.21	-0.21	14.86

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22
Ratios
ROE (%)	26.98	30.56	20.83	-23.01	-21.47	-121.43	N/A	N/A	N/A	N/A
ROCE (%)	31.48	33.5	10.43	-2.33	1.06	-5	N/A	N/A	N/A	N/A
Asset Turnover Ratio	1.32	1.12	0.54	0.39	0.42	0.44	0.48	0.57	0.47	0.65
PAT to CFO Conversion(x)	0.72	0.88	1.83	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	59	81	91	77	71	69	63	55	54	41
Inventory Days	30	24	30	47	46	41	52	55	62	47
Payable Days	97	126	143	62	42	66	107	96	99	59

Ahlcon Parenterals (India) Ltd Stock News

Ahlcon Parenterals (India) Ltd FAQs

What is the share price of Ahlcon Parenteral (I?

Company share prices are keep on changing according to the market conditions. The closing price of Ahlcon Parenteral (I on 01-Jan-1970 05:30 is ₹0.00.

What is the market cap of Ahlcon Parenteral (I?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Ahlcon Parenteral (I stood at ₹370.8.

What is the P/E ratio of Ahlcon Parenteral (I?

The latest P/E ratio of Ahlcon Parenteral (I as of 01-Jan-1970 05:30 is 0.00.

What is the P/B ratio of Ahlcon Parenteral (I?

The latest P/B ratio of Ahlcon Parenteral (I as of 01-Jan-1970 05:30 is 4.31.

What is the 52-week high and low of Ahlcon Parenteral (I?

The 52-week high of Ahlcon Parenteral (I is ₹517.2 and the 52-week low is ₹514.8.

What is the TTM revenue of Ahlcon Parenteral (I?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Ahlcon Parenteral (I is ₹175.7 ( Cr.) .

About Ahlcon Parenterals (India) Ltd

Ahlcon Parenterals (India), incorporated in 1992, is engaged in manufacturing life saving Intravenous fluids and medical disposals by employing a highly sophisticated production process, the aseptic form-fill-seal technology imported from Switzerland.

Ahlcon has an installed capacity of 30 million bottles per annum for LVP in pack size of 100ml and 500ml. Further, 200ml and 300ml packs are being launched in near future.

The company also has capacity of 60 million vials of eye drops and injections in the fill size of 2ml, 3ml, 5ml & 10ml both in transparent and white opaque packs as SVP.

Within a short span of time since its inception, the company has achieved the quality certification from WHO-GMP International and ISO 9002, a landmark achievement which ensures international quality standards with ultimate objective of getting the MCA approval.

Products

Antimicrobial I V fluids, eye and ear drops, ointments, other products such as respiratory solutions, plasma volume expander and many more.